These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 10679286)
1. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations. Iwashita T; Murakami H; Kurokawa K; Kawai K; Miyauchi A; Futami H; Qiao S; Ichihara M; Takahashi M Biochem Biophys Res Commun; 2000 Feb; 268(3):804-8. PubMed ID: 10679286 [TBL] [Abstract][Full Text] [Related]
2. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Miyauchi A; Futami H; Hai N; Yokozawa T; Kuma K; Aoki N; Kosugi S; Sugano K; Yamaguchi K Jpn J Cancer Res; 1999 Jan; 90(1):1-5. PubMed ID: 10076558 [TBL] [Abstract][Full Text] [Related]
3. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Iwashita T; Kato M; Murakami H; Asai N; Ishiguro Y; Ito S; Iwata Y; Kawai K; Asai M; Kurokawa K; Kajita H; Takahashi M Oncogene; 1999 Jul; 18(26):3919-22. PubMed ID: 10445857 [TBL] [Abstract][Full Text] [Related]
4. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671 [TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations. Takahashi M; Asai N; Iwashita T; Murakami H; Ito S J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851 [TBL] [Abstract][Full Text] [Related]
6. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Smith DP; Houghton C; Ponder BA Oncogene; 1997 Sep; 15(10):1213-7. PubMed ID: 9294615 [TBL] [Abstract][Full Text] [Related]
7. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703 [TBL] [Abstract][Full Text] [Related]
8. Germ line mutation in the RET proto-oncogene associated with familial multiple endocrine neoplasia type 2B: a case report. Ishida O; Zeki K; Morimoto I; Yamamoto S; Fujihira T; Eto S Jpn J Clin Oncol; 1995 Jun; 25(3):104-8. PubMed ID: 7596047 [TBL] [Abstract][Full Text] [Related]
9. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112 [TBL] [Abstract][Full Text] [Related]
10. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. Gimm O; Marsh DJ; Andrew SD; Frilling A; Dahia PL; Mulligan LM; Zajac JD; Robinson BG; Eng C J Clin Endocrinol Metab; 1997 Nov; 82(11):3902-4. PubMed ID: 9360560 [TBL] [Abstract][Full Text] [Related]
11. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B. Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113 [TBL] [Abstract][Full Text] [Related]
12. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446 [TBL] [Abstract][Full Text] [Related]
13. RET activation by germline MEN2A and MEN2B mutations. Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194 [TBL] [Abstract][Full Text] [Related]
14. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. Asai N; Murakami H; Iwashita T; Takahashi M J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426 [TBL] [Abstract][Full Text] [Related]
15. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Santoro M; Carlomagno F; Romano A; Bottaro DP; Dathan NA; Grieco M; Fusco A; Vecchio G; Matoskova B; Kraus MH Science; 1995 Jan; 267(5196):381-3. PubMed ID: 7824936 [TBL] [Abstract][Full Text] [Related]
17. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Jasim S; Ying AK; Waguespack SG; Rich TA; Grubbs EG; Jimenez C; Hu MI; Cote G; Habra MA Thyroid; 2011 Feb; 21(2):189-92. PubMed ID: 21186952 [TBL] [Abstract][Full Text] [Related]
18. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential. Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701 [TBL] [Abstract][Full Text] [Related]
19. RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature. Kahn MA; Cote GJ; Gagel RF Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1996 Sep; 82(3):288-94. PubMed ID: 8884827 [TBL] [Abstract][Full Text] [Related]
20. De novo RET proto-oncogene mutation in a patient with multiple endocrine neoplasia type 2B. Chang TJ; Wu SL; Chang TC; Huang SH; Chang TJ J Formos Med Assoc; 1999 Oct; 98(10):692-7. PubMed ID: 10575840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]